Literature DB >> 479265

Cyclophosphamide-resistant Yoshida ascites tumor cells and their cross resistance to some alkylating agents.

H H Gerhartz, E Liss, H Schmidt.   

Abstract

A cyclophosphamide-resistant subline of a Yoshida ascites tumor was developed by giving increasing doses of the drug after transplantation. The effect of several alkylating agents on the cell proliferation of both the sensitive and resistance cell line was compared establishind dose response curves and D50 values. The developed subline revealed a 260 fold resistance to cyclophosphamide. It was completely cross-resistant to hydroperoxycyclophosphamide, whereas for triaziquone, N-oxide-mustard, and N-methyl-mustard only a partial cross resistance existed. These results give further evidence that cyclophosphamide and hydropeoxycyclophosphamide have the same mechanism of action. Regarding the other alkylating agents the results demonstrate differences concerning either the molecular mode of action or protecting effects. A decreased activation or uptake of substance is probably not the base for resistance.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 479265     DOI: 10.1007/bf00419285

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  21 in total

1.  Cytokinetic aspects of clinical drug resistance.

Authors:  R A Bender; R L Dedrick
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  [Estimation of tumor sensitivity in vitro. I. Comparative studies with the Jensen sarcoma in vivo and in vitro after 1-hour-incubation].

Authors:  H J Seidel; L A Wegner
Journal:  Z Krebsforsch       Date:  1969

3.  [Oncobiogram and therapy success in transplantation neoplasms].

Authors:  M Volm; G Bastert; J Mattern; K Wayss
Journal:  Naturwissenschaften       Date:  1973-08

4.  [Inhibition of desoxyribonucleic acid (DNA) synthesis and modification of cell multiplication of Yoshida ascites tumor cells by alkylating substances].

Authors:  E Liss; A Reinecke; G Palme
Journal:  Arzneimittelforschung       Date:  1969-07

Review 5.  Conference on obstacles to the control of acute leukemia. Studies on cross-resistance and collateral sensitivity (1962-1964).

Authors:  D J Hutchison
Journal:  Cancer Res       Date:  1965-10       Impact factor: 12.701

6.  A study on the mechanism of resistance to nitrogen mustard (HN2) in Ehrlich ascites tumor cells: comparison of uptake of HN2-14-C into sensitive and resistant cells.

Authors:  M K Wolpert; R W Ruddon
Journal:  Cancer Res       Date:  1969-04       Impact factor: 12.701

7.  Differences in the in vivo alkylation and cross-linking of nitrogen mustard-sensitive and -resistant lines of Lettré-Ehrlich asites tumors.

Authors:  E H Chun; L Gonzales; F S Lewis; J Jones; R J Rutman
Journal:  Cancer Res       Date:  1969-06       Impact factor: 12.701

8.  The enzymatic basis of the selective action of cyclophosphamide.

Authors:  P J Cox; B J Phillips; P Thomas
Journal:  Cancer Res       Date:  1975-12       Impact factor: 12.701

9.  Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.

Authors:  U Draeger; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

10.  Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.

Authors:  J Draeger; G Peter; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04
View more
  1 in total

1.  A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.

Authors:  K Satoh; N Kan; T Okino; M Nakanishi; K Mise; Y Teramura; S Yamasaki; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.